Ensysce Biosciences (ENSC) Reports Q4

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. SPY
10. PNC

Go back to Ensysce Biosciences (ENSC) Reports Q4

Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

March 30, 2023 5:38 PM EDT

~ Corporate Update Call to be Held Tuesday, April 11, 2023 ~

SAN DIEGO, CA / ACCESSWIRE / March 30, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2022.

Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our focus remains on execution and advancing clinical development plans for our programs that provide strong pain relief using our PF614 and... More